Cyberonics’ Sharpened Focus Buoys Stock 13% In May; OTC Index Off 2.6%
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics' revised NCP vagus nerve stimulation development plan for depression, combined with a sharper focus on epilepsy and fiscal fourth-quarter performance ahead of Wall Street expectations, led to a 12.5% stock gain in May